Title :

Estimates of epidemiology, mortality and disease burden associated with progressive fibrosing interstitial lung disease in france (the progress study)

Author(s) :

Nasser, Mouhamad [Auteur]
Infections Virales et Pathologie Comparée - UMR 754 [IVPC]
Université Claude Bernard Lyon 1 [UCBL]
Hôpital Louis Pradel [CHU - HCL]
Larrieu, Sophie [Auteur]
IQVIA
Boussel, Loic [Auteur]
Hospices Civils de Lyon [HCL]
Si-Mohamed, Salim [Auteur]
Université Claude Bernard Lyon 1 [UCBL]
Hospices Civils de Lyon [HCL]
Centre de Recherche en Acquisition et Traitement de l'Image pour la Santé [CREATIS]
Bazin, Fabienne [Auteur]
IQVIA
Marque, Sebastien [Auteur]
IQVIA
Massol, Jacques [Auteur]
Thivolet-Bejui, Francoise [Auteur]
Hospices Civils de Lyon [HCL]
Chalabreysse, Lara [Auteur]
Hospices Civils de Lyon [HCL]
Maucort-Boulch, Delphine [Auteur]
Université de Lyon
Service de Biostatistiques [Lyon]
Laboratoire de Biométrie et Biologie Evolutive - UMR 5558 [LBBE]
Hospices Civils de Lyon [HCL]
Hachulla, Eric [Auteur]
Centre National de Référence des Maladies Auto-Immunes Systémiques Rares du Nord et Nord-Ouest de France [CeRAINO]
Institut de Recherche Translationnelle sur l'Inflammation (INFINITE) - U1286
Jouneau, Stephane [Auteur]
Centre Hospitalier Universitaire [Rennes]
Institut de recherche en santé, environnement et travail [Irset]
École des Hautes Études en Santé Publique [EHESP] [EHESP]
Le Lay, Katell [Auteur]
Boehringer Ingelheim
Cottin, Vincent [Auteur]
Infections Virales et Pathologie Comparée - UMR 754 [IVPC]
Université Claude Bernard Lyon 1 [UCBL]
Centre national de référence des maladies pulmonaires rares [Lyon] [CRMPM]
Hôpital Louis Pradel [CHU - HCL]

Journal title :

Respiratory Research

Abbreviated title :

Respir Res

Volume number :

22

Pages :

162

Publication date :

2021-05-24

ISSN :

1465-993X

Keyword(s) :

Algorithms
Epidemiology
Progressive fibrosis
Interstitial lung disease
Healthcare resource utilisation

HAL domain(s) :

Sciences du Vivant [q-bio]

English abstract : [en]

BACKGROUND: There is a paucity of data on the epidemiology, survival estimates and healthcare resource utilisation and associated costs of patients with progressive fibrosing interstitial lung disease (PF-ILD) in France. ...
Show more >BACKGROUND: There is a paucity of data on the epidemiology, survival estimates and healthcare resource utilisation and associated costs of patients with progressive fibrosing interstitial lung disease (PF-ILD) in France. An algorithm for extracting claims data was developed to indirectly identify and describe patients with PF-ILD in the French national administrative healthcare database. METHODS: The French healthcare database, the Système National des Données de Santé (SNDS), includes data related to ambulatory care, hospitalisations and death for 98.8% of the population. In this study, algorithms based on age, diagnosis and healthcare consumption were created to identify adult patients with PF-ILD other than idiopathic pulmonary fibrosis between 2010 and 2017. Incidence, prevalence, survival estimates, clinical features and healthcare resource usage and costs were described among patients with PF-ILD. RESULTS: We identified a total of 14,413 patients with PF-ILD. Almost half of them (48.1%) were female and the mean (± standard deviation) age was 68.4 (± 15.0) years. Between 2010 and 2017, the estimated incidence of PF-ILD ranged from 4.0 to 4.7/100,000 person-years and the estimated prevalence from 6.6 to 19.4/100,000 persons. The main diagnostic categories represented were exposure-related ILD other than hypersensitivity pneumonitis (n = 3486; 24.2%), idiopathic interstitial pneumonia (n = 3113; 21.6%) and rheumatoid arthritis-associated ILD (n = 2521; 17.5%). Median overall survival using Kaplan-Meier estimation was 3.7 years from the start of progression. During the study, 95.2% of patients had ≥ 1 hospitalisation for respiratory care and 34.3% were hospitalised in an intensive care unit. The median (interquartile range) total specific cost per patient during the follow-up period was €25,613 (10,622-54,287) and the median annual cost per patient was €18,362 (6856-52,026), of which €11,784 (3003-42,097) was related to hospitalisations. Limitations included the retrospective design and identification of cases through an algorithm in the absence of chest high-resolution computed tomography scans and pulmonary function tests. CONCLUSIONS: This large, real-world, longitudinal study provides important insights into the characteristics, epidemiology and healthcare resource utilisation and costs associated with PF-ILD in France using a comprehensive and exhaustive database, and provides vital evidence that PF-ILD represents a high burden on both patients and healthcare services. Trial registration ClinicalTrials.gov, NCT03858842. ISRCTN, ISRCTN12345678. Registered 3 January 2019-Retrospectively registered, https://clinicaltrials.gov/ct2/show/NCT03858842.Show less >

Language :

Anglais

Peer reviewed article :

Oui

Audience :

Internationale

Popular science :

Non

Administrative institution(s) :

CHU Lille
Inserm
Université de Lille

Collections :

• Institut de Recherche Translationnelle sur l'Inflammation (INFINITE) - U1286

Submission date :

2021-07-06T12:51:06Z
2024-03-04T14:56:41Z